CLINICAL STUDIES

Teijin TMX-049DN-201

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess Safety, Tolerability, and Renal Effects of TMX-049 in Subjects with Type 2 Diabetes and Albuminuria

Study Phase:

Phase 2

Criteria:

  • Male or Female 18 years or older
  • Taking ACE or ARB
  • History of high Albuminuria
Register